| (Values in U.S. Thousands) | Mar, 2026 | Mar, 2025 | Mar, 2024 | Mar, 2023 | Mar, 2022 |
| Sales | 10 | 10 | 160 | 10 | 0 |
| Sales Growth | unch | -93.75% | +1,500.00% | unch | -100.00% |
| Net Income | -5,020 | -6,060 | -6,730 | -5,460 | -1,710 |
| Net Income Growth | +17.16% | +9.96% | -23.26% | -219.30% | -163.08% |
Virax Biolabs Group Limited (VRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Virax Biolabs Group Limited is a biotechnology company focused on the prevention, detection, and diagnosis of viral diseases as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus. Virax Biolabs Group Limited is based in London, United Kingdom.
Fiscal Year End Date: 03/31